For patients with high-risk non–muscle-invasive bladder cancer (NMIBC), the gold-standard systemic therapy for preventing disease recurrence and progression following transurethral resection is ...
The PD-1 inhibitor sasanlimab showed anti-tumor activity and manageable safety in combination with BCG induction and maintenance compared with standard of care in patients with BCG-naïve high-risk ...
After matching, standardized mean differences were <0.1 for all key covariates. NAI + BCG showed improved outcomes versus other bladder sparing therapies in the d-uo cohort, including increased ...
NCCN now includes Anktiva plus BCG for BCG-unresponsive papillary-only NMIBC, acknowledging an unmet need in patients without CIS who have limited post-BCG options. Radical cystectomy remains ...
SUZHOU, China, Feb. 26, 2026 /PRNewswire/ -- Intravesical BCG is the standard of care (SOC) for BCG-naïve high-risk non-muscle-invasive bladder cancer (NMIBC) patients. However, the scarcity of BCG ...
The BCG vaccine was introduced in 1921 and remains the only licensed vaccine for the prevention of TB worldwide. Despite its extensive use, the BCG vaccine lacks the ability to fully control the ...
Study findings fill in the evidence gap during the current BCG shortage, while data from randomized clinical trials are pending. Compared with bacillus Calmette-Guérin (BCG) therapy, sequential ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results